A Novel Approach to Cancer Therapy using PX-478 as a HIF-1α Inhibitor

被引：64

作者：

Lee, Kyeong ^{[2
]}

Kim, Hwan Mook ^{[1
]}

机构：

[1] Gachon Univ Med & Sci, Coll Pharm, Inchon 406799, South Korea

[2] Dongguk Univ Seoul, Coll Pharm, Seoul 100715, South Korea

来源：

ARCHIVES OF PHARMACAL RESEARCH | 2011年 / 34卷 / 10期

关键词：

HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; FACTOR-I; RADIOSENSITIZATION;

D O I：

10.1007/s12272-011-1021-3

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Hypoxia-inducible factor-l alpha (HIF-1 alpha) is a transcription factor produced by tumor cells under hypoxic conditions, and a key regulator of a number of genes important in cancer biology. Over-expression of HIF-1 alpha in human tumors is associated with poor prognosis and poor therapeutic outcomes and HIF-1 alpha has been suggested as a novel target for cancer therapy. This article provides a review of PX-478 as the first novel HIF-1 alpha inhibitor in clinical stage for the treatment of solid tumors.

引用

下载

页码：1583 / 1585

页数：3

共 50 条

[1] A novel approach to cancer therapy using PX-478 as a HIF-1α inhibitor
Kyeong Lee
Hwan Mook Kim
Archives of Pharmacal Research, 2011, 34 : 1583 - 1585
[2] Enhanced antitumor activity of the HIF-1 inhibitor PX-478 combined with radiation and chemotherapy in pancreatic cancer
Powis, Garth
Von Hoff, Daniel
Bankson, James
Lemos, Robert
Hostetter, Galen
Demeure, Michael
Schwartz, David
MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
[3] PX-478, an HIF-1α inhibitor, impairs mesoCAR T cell antitumor function in cervical cancer
Meymandi, Ahmad Reza Panahi
Akbari, Behnia
Soltantoyeh, Tahereh
Shahosseini, Zahra
Hosseini, Mina
Hadjati, Jamshid
Mirzaei, Hamid Reza
FRONTIERS IN ONCOLOGY, 2024, 14
[4] HIF-1α inhibitor PX-478 preserves pancreatic. cell function in diabetes
Ilegems, Erwin
Bryzgalova, Galyna
Correia, Jorge
Yesildag, Burcak
Berra, Edurne
Ruas, Jorge L.
Pereira, Teresa S.
Berggren, Per-Olof
SCIENCE TRANSLATIONAL MEDICINE, 2022, 14 (638)
[5] Radiosensitization and Stromal Imaging Response Correlates for the HIF-1 Inhibitor PX-478 Given with or without Chemotherapy in Pancreatic Cancer
Schwartz, David L.
Bankson, James A.
Lemos, Robert, Jr.
Lai, Stephen Y.
Thittai, Arun K.
He, Yi
Hostetter, Galen
Demeure, Michael J.
Von Hoff, Daniel D.
Powis, Garth
MOLECULAR CANCER THERAPEUTICS, 2010, 9 (07) : 2057 - 2067
[6] PX-478, a potent inhibitor of hypoxia-inducible factor-1 (HIF-1) and antitumor agent
Welsh, SJ
Williams, RR
Kirkpatrick, DL
Powis, G
EUROPEAN JOURNAL OF CANCER, 2002, 38 : S90 - S90
[7] Results from a phase I, dose-escalation study of PX-478, and orally available inhibitor of HIF-1α
Tibes, R.
Falchook, G. S.
Von Hoff, D. D.
Weiss, G. J.
Iyengar, T.
Kurzrock, R.
Pestano, L.
Lowe, A. M.
Herbst, R. S.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[8] Inhibition of HIF-1α by PX-478 suppresses tumor growth of esophageal squamous cell cancer in vitro and in vivo
Zhu, Yingming
Zang, Yuanwei
Zhao, Fen
Li, Zhenxiang
Zhang, Jianbo
Fang, Liang
Li, Minghuan
Xing, Ligang
Xu, Zhonghua
Yu, Jinming
AMERICAN JOURNAL OF CANCER RESEARCH, 2017, 7 (05): : 1198 - +
[9] PX-478, a Novel Small Molecule Inhibitor of Hypoxia Inducible Factor-1 (HIF-1) Downregulates HIF and Induces Cytotoxicity in Diffuse Large B Cell Lymphoma Cells
Bhalla, Savita
Gordon, Leo I.
Singh, Amareshwar
Ahmed, Sairah
Dokic, Danijela
James, Crystal
Schumacker, Paul T.
Evens, Andrew M.
BLOOD, 2009, 114 (22) : 1062 - 1063
[10] Treatment with HIF-1α Antagonist PX-478 Inhibits Progression and Spread of Orthotopic Human Small Cell Lung Cancer and Lung Adenocarcinoma in Mice
Jacoby, Joerg J.
Erez, Baruch
Korshunova, Maria V.
Williams, Ryan R.
Furutani, Kazuhisa
Takahashi, Osamu
Kirkpatrick, Lynn
Lippman, Scott M.
Powis, Garth
O'Reilly, Michael S.
Herbst, Roy S.
JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (07) : 940 - 949

← 1 2 3 4 5 →